Antares Pharma, Inc. (ATRS)

[H2R]

US testosterone market 6.5 million prescriptions

From SoS's https://smithonstocks.com/antares-xyosted-is-approved-let-the-good-times-roll-atrs-buy-3-77/

a couple of snippets:

The testosterone market in the US consisted of about 6.5 million prescriptions in 2017 and is growing at about 5% this year and on track to reach 6.8 million. About 70% of this market is comprised of injectable dosage forms with the remaining 30% almost entirely gels.

With best in class characteristics for an injectable product, Xyosted should capture a very meaningful part of the addressable market.

Larry goes over numbers and markets to show medium to long term the contribution to the EPS and impact on the PPS. Looking good!

Best of luck in your investments. I'll be staying in this Company for "a while", at least a handful of quarters.